{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:08:41Z","timestamp":1793758121265,"version":"4.6.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2020KY007, 2021KY006 and 2022KY001"],"award-info":[{"award-number":["2020KY007, 2021KY006 and 2022KY001"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key Construction Disciplines of Provincial and Municipal Co construction of Zhejiang","award":["NO.2023-SSGJ-002"],"award-info":[{"award-number":["NO.2023-SSGJ-002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-024-09899-5","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T10:02:29Z","timestamp":1726221749000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Comparison of cefiderocol and colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review with meta-analysis and trial sequential analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Yangyang","family":"Zhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5796-5987","authenticated-orcid":false,"given":"Wenchao","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Difan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changqin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,13]]},"reference":[{"issue":"9","key":"9899_CR1","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.3390\/antibiotics11091263","volume":"11","author":"N Coppola","year":"2022","unstructured":"Coppola N, Maraolo AE, Onorato L, et al. Epidemiology, mechanisms of Resistance and Treatment Algorithm for infections due to Carbapenem-Resistant Gram-negative Bacteria: an Expert Panel Opinion. Antibiot (Basel). 2022;11(9):1263. https:\/\/doi.org\/10.3390\/antibiotics11091263.","journal-title":"Antibiot (Basel)"},{"issue":"1","key":"9899_CR2","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1080\/22221751.2022.2093134","volume":"11","author":"C Liu","year":"2022","unstructured":"Liu C, Chen K, Wu Y, et al. Epidemiological and genetic characteristics of clinical carbapenem-resistant Acinetobacter baumannii strains collected countrywide from hospital intensive care units (ICUs) in China. Emerg Microbes Infect. 2022;11(1):1730\u201341. https:\/\/doi.org\/10.1080\/22221751.2022.2093134.","journal-title":"Emerg Microbes Infect"},{"issue":"4","key":"9899_CR3","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","volume":"18","author":"M Paul","year":"2018","unstructured":"Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18(4):391\u2013400. https:\/\/doi.org\/10.1016\/S1473-3099(18)30099-9.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"9899_CR4","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/cid\/ciy988","volume":"69","author":"Y Dickstein","year":"2019","unstructured":"Dickstein Y, Lellouche J, Ben Dalak Amar M, AIDA Study Group, et al. Treatment outcomes of colistin- and carbapenem-resistant Acinetobacter baumannii infections: an exploratory subgroup analysis of a Randomized Clinical Trial. Clin Infect Dis. 2019;69(5):769\u201376. https:\/\/doi.org\/10.1093\/cid\/ciy988.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"9899_CR5","doi-asserted-by":"publisher","first-page":"S179","DOI":"10.1093\/cid\/ciad094","volume":"76","author":"RK Shields","year":"2023","unstructured":"Shields RK, Paterson DL, Tamma PD. Navigating available treatment options for Carbapenem-Resistant Acinetobacter baumannii-Calcoaceticus Complex infections. Clin Infect Dis. 2023;76(Suppl 2):S179\u201393. https:\/\/doi.org\/10.1093\/cid\/ciad094.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"9899_CR6","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","volume":"74","author":"PD Tamma","year":"2022","unstructured":"Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America Guidance on the treatment of AmpC \u03b2-Lactamase-producing enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections. Clin Infect Dis. 2022;74(12):2089\u2013114. https:\/\/doi.org\/10.1093\/cid\/ciab1013.","journal-title":"Clin Infect Dis"},{"key":"9899_CR7","doi-asserted-by":"publisher","unstructured":"Tamma PD, Aitken SL, Bonomo RA et al. Infectious Diseases Society of America 2023 Guidance on the treatment of Antimicrobial resistant gram-negative infections. Clin Infect Dis 2023 Jul 18:ciad428. https:\/\/doi.org\/10.1093\/cid\/ciad428","DOI":"10.1093\/cid\/ciad428"},{"issue":"2","key":"9899_CR8","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/cid\/ciac268","volume":"75","author":"PD Tamma","year":"2022","unstructured":"Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America 2022 Guidance on the treatment of extended-spectrum \u03b2-lactamase Producing enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat Resistance (DTR-P. aeruginosa). Clin Infect Dis. 2022;75(2):187\u2013212. https:\/\/doi.org\/10.1093\/cid\/ciac268.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"9899_CR9","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","volume":"28","author":"M Paul","year":"2022","unstructured":"Paul M, Carrara E, Retamar P, et al. European Society of Clinical Microbiology and Infectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect. 2022;28(4):521\u201347. https:\/\/doi.org\/10.1016\/j.cmi.2021.11.025.","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"9899_CR10","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1080\/14787210.2022.2020099","volume":"20","author":"TP Lodise","year":"2022","unstructured":"Lodise TP, Bassetti M, Ferrer R, et al. All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies. Expert Rev Anti Infect Ther. 2022;20(5):707\u201319. Epub 2022 Jan 12.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"10","key":"9899_CR11","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1093\/cid\/ciz1146","volume":"71","author":"Y Dickstein","year":"2020","unstructured":"Dickstein Y, Lellouche J, Schwartz D, et al. AIDA Study Group. Colistin Resistance Development following colistin-meropenem combination therapy Versus Colistin Monotherapy in patients with infections caused by Carbapenem-Resistant Organisms. Clin Infect Dis. 2020;71(10):2599\u2013607. https:\/\/doi.org\/10.1093\/cid\/ciz1146.","journal-title":"Clin Infect Dis"},{"key":"9899_CR12","doi-asserted-by":"publisher","unstructured":"Kaye KS, Marchaim D, Thamlikitkul V, et al. Colistin Monotherapy versus Combination Therapy for Carbapenem-resistant organisms. NEJM Evid. 2023;2(1). https:\/\/doi.org\/10.1056\/evidoa2200131. Epub 2022 Dec 6.","DOI":"10.1056\/evidoa2200131"},{"key":"9899_CR13","doi-asserted-by":"publisher","unstructured":"Wagenlehner F, Lucenteforte E, Pea F et al. Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins. Clin Microbiol Infect. 2021 Jan 6:S1198-743X(20)30764-3. https:\/\/doi.org\/10.1016\/j.cmi.2020.12.009. Epub ahead of print.","DOI":"10.1016\/j.cmi.2020.12.009"},{"key":"9899_CR14","unstructured":"World Health Organization. 2021. WHO publishes list of bacteria for which new antibiotics are urgently needed.(https:\/\/www.who.int\/news\/item\/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed)"},{"issue":"3","key":"9899_CR15","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40265-019-1055-2","volume":"79","author":"GG Zhanel","year":"2019","unstructured":"Zhanel GG, Golden AR, Zelenitsky S, et al. Cefiderocol: a Siderophore cephalosporin with activity against Carbapenem-resistant and Multidrug-Resistant Gram-Negative Bacilli. Drugs. 2019;79(3):271\u201389. https:\/\/doi.org\/10.1007\/s40265-019-1055-2.","journal-title":"Drugs"},{"issue":"2","key":"9899_CR16","doi-asserted-by":"publisher","first-page":"106882","DOI":"10.1016\/j.ijantimicag.2023.106882","volume":"62","author":"M Kollef","year":"2023","unstructured":"Kollef M, Dupont H, Greenberg DE, et al. Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: review of the evidence. Int J Antimicrob Agents. 2023;62(2):106882. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106882. Epub 2023 Jun 8.","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"9899_CR17","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","volume":"120","author":"A Khwaja","year":"2012","unstructured":"Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179\u201384. https:\/\/doi.org\/10.1159\/000339789.","journal-title":"Nephron Clin Pract"},{"issue":"9","key":"9899_CR18","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135. https:\/\/doi.org\/10.1007\/s10654-010-9491-z. Epub 2010 Jul 22.","journal-title":"Eur J Epidemiol"},{"issue":"4","key":"9899_CR19","doi-asserted-by":"publisher","first-page":"dlab174","DOI":"10.1093\/jacamr\/dlab174","volume":"3","author":"R Pascale","year":"2021","unstructured":"Pascale R, Pasquini Z, Bartoletti M, et al. Cefiderocol treatment for carbapenem resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study. JAC Antimicrob Resist. 2021;3(4):dlab174. https:\/\/doi.org\/10.1093\/jacamr\/dlab174.","journal-title":"JAC Antimicrob Resist"},{"issue":"5","key":"9899_CR20","doi-asserted-by":"publisher","first-page":"e0214221","DOI":"10.1128\/aac.02142-21","volume":"66","author":"M Falcone","year":"2022","unstructured":"Falcone M, Tiseo G, Leonildi A, et al. Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by Carbapenem-Resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2022;66(5):e0214221. https:\/\/doi.org\/10.1128\/aac.02142-21.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"9899_CR21","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1007\/s40121-023-00854-6","volume":"12","author":"DF Bavaro","year":"2023","unstructured":"Bavaro DF, Papagni R, Belati A, et al. Cefiderocol Versus Colistin for the treatment of Carbapenem-Resistant Acinetobacter baumannii Complex Bloodstream infections: a retrospective, propensity-score adjusted, Monocentric Cohort Study. Infect Dis Ther. 2023;12(8):2147\u201363. https:\/\/doi.org\/10.1007\/s40121-023-00854-6.","journal-title":"Infect Dis Ther"},{"issue":"6","key":"9899_CR22","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.3390\/antibiotics12061048","volume":"12","author":"L Dalfino","year":"2023","unstructured":"Dalfino L, Stufano M, Bavaro DF, et al. Effectiveness of First-Line therapy with Old and Novel antibiotics in Ventilator-Associated Pneumonia caused by Carbapenem-Resistant Acinetobacter baumannii: a real life, prospective, observational, single-center study. Antibiot (Basel). 2023;12(6):1048. https:\/\/doi.org\/10.3390\/antibiotics12061048.","journal-title":"Antibiot (Basel)"},{"issue":"4","key":"9899_CR23","doi-asserted-by":"publisher","first-page":"984","DOI":"10.3390\/microorganisms11040984","volume":"11","author":"M Mazzitelli","year":"2023","unstructured":"Mazzitelli M, Gregori D, Sasset L, et al. Cefiderocol-based versus colistin-based regimens for severe carbapenem-resistant Acinetobacter baumannii infections: a propensity Score-Weighted, Retrospective Cohort Study during the first two years of the COVID-19 pandemic. Microorganisms. 2023;11(4):984. https:\/\/doi.org\/10.3390\/microorganisms11040984.","journal-title":"Microorganisms"},{"issue":"1","key":"9899_CR24","doi-asserted-by":"publisher","first-page":"106825","DOI":"10.1016\/j.ijantimicag.2023.106825","volume":"62","author":"A Russo","year":"2023","unstructured":"Russo A, Bruni A, Gull\u00ec S, et al. Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19. Int J Antimicrob Agents. 2023;62(1):106825. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106825.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"9899_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12879-021-07024-4","volume":"22","author":"JM Pogue","year":"2022","unstructured":"Pogue JM, Zhou Y, Kanakamedala H, Cai B. Burden of illness in carbapenem-resistant Acinetobacter baumannii infections in US hospitals between 2014 and 2019. BMC Infect Dis. 2022;22(1):36. https:\/\/doi.org\/10.1186\/s12879-021-07024-4.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"9899_CR26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/jac\/dkx368","volume":"73","author":"K Kengkla","year":"2018","unstructured":"Kengkla K, Kongpakwattana K, Saokaew S, et al. Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis. J Antimicrob Chemother. 2018;73(1):22\u201332. https:\/\/doi.org\/10.1093\/jac\/dkx368.","journal-title":"J Antimicrob Chemother"},{"key":"9899_CR27","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jgar.2020.08.021","volume":"24","author":"J Liu","year":"2021","unstructured":"Liu J, Shu Y, Zhu F, et al. Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: a systematic review and network meta-analysis. J Glob Antimicrob Resist. 2021;24:136\u201347. Epub 2020 Sep 2.","journal-title":"J Glob Antimicrob Resist"},{"issue":"3","key":"9899_CR28","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jhin.2017.11.014","volume":"98","author":"M Ayd\u0131n","year":"2018","unstructured":"Ayd\u0131n M, Erg\u00f6n\u00fcl \u00d6, Azap A, et al. Turkish Society of Clinical Microbiology and Infectious diseases, Healthcare-Related Infections Study Group, Turkey. Rapid emergence of colistin resistance and its impact on fatality among healthcare-associated infections. J Hosp Infect. 2018;98(3):260\u20133. Epub 2017 Dec 15.","journal-title":"J Hosp Infect"},{"issue":"1","key":"9899_CR29","doi-asserted-by":"publisher","first-page":"2317915","DOI":"10.1080\/22221751.2024.2317915","volume":"13","author":"Q Luo","year":"2024","unstructured":"Luo Q, Lu P, Chen Y, et al. ESKAPE in China: epidemiology and characteristics of antibiotic resistance. Emerg Microbes Infect. 2024;13(1):2317915. https:\/\/doi.org\/10.1080\/22221751.2024.2317915. Epub 2024 Feb 23.","journal-title":"Emerg Microbes Infect"},{"issue":"3","key":"9899_CR30","doi-asserted-by":"publisher","first-page":"dlaa060","DOI":"10.1093\/jacamr\/dlaa060","volume":"2","author":"C Longshaw","year":"2020","unstructured":"Longshaw C, Manissero D, Tsuji M, Echols R, Yamano Y. In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible gram-negative bacteria from Europe. JAC Antimicrob Resist. 2020;2(3):dlaa060. https:\/\/doi.org\/10.1093\/jacamr\/dlaa060.","journal-title":"JAC Antimicrob Resist"},{"issue":"2","key":"9899_CR31","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","volume":"21","author":"M Bassetti","year":"2021","unstructured":"Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21(2):226\u201340. https:\/\/doi.org\/10.1016\/S1473-3099(20)30796-9. Epub 2020 Oct 12.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"9899_CR32","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","volume":"21","author":"RG Wunderink","year":"2021","unstructured":"Wunderink RG, Matsunaga Y, Ariyasu M, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2021;21(2):213\u201325. https:\/\/doi.org\/10.1016\/S1473-3099(20)30731-3. Epub 2020 Oct 12.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"9899_CR33","doi-asserted-by":"publisher","first-page":"106113","DOI":"10.1016\/j.jinf.2024.01.012","volume":"88","author":"L Onorato","year":"2024","unstructured":"Onorato L, de Luca I, Monari C, Coppola N. Cefiderocol either in monotherapy or combination versus best available therapy in the treatment of carbapenem-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis. J Infect. 2024;88(3):106113. https:\/\/doi.org\/10.1016\/j.jinf.2024.01.012. Epub 2024 Feb 6.","journal-title":"J Infect"},{"issue":"7","key":"9899_CR34","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1093\/jac\/dkz123","volume":"74","author":"T Katsube","year":"2019","unstructured":"Katsube T, Saisho Y, Shimada J, Furuie H. Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects. J Antimicrob Chemother. 2019;74(7):1971\u20134. https:\/\/doi.org\/10.1093\/jac\/dkz123.","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 7","key":"9899_CR35","doi-asserted-by":"publisher","first-page":"S552","DOI":"10.1093\/cid\/ciz828","volume":"69","author":"T Katsube","year":"2019","unstructured":"Katsube T, Echols R, Wajima T. Pharmacokinetic and pharmacodynamic profiles of Cefiderocol, a Novel Siderophore Cephalosporin. Clin Infect Dis. 2019;69(Suppl 7):S552\u20138. https:\/\/doi.org\/10.1093\/cid\/ciz828.","journal-title":"Clin Infect Dis"},{"key":"9899_CR36","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jgar.2021.10.014","volume":"27","author":"M Gatti","year":"2021","unstructured":"Gatti M, Bartoletti M, Cojutti PG, Gaibani P, Conti M, Giannella M, Viale P, Pea F. A descriptive case series of pharmacokinetic\/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and\/or ventilator-associated pneumonia treated with cefiderocol. J Glob Antimicrob Resist. 2021;27:294\u20138. https:\/\/doi.org\/10.1016\/j.jgar.2021.10.014. Epub 2021 Oct 26.","journal-title":"J Glob Antimicrob Resist"},{"issue":"2","key":"9899_CR37","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/14787210.2023.2169131","volume":"21","author":"M Gatti","year":"2023","unstructured":"Gatti M, Pea F. Jumping into the future: overcoming pharmacokinetic\/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams. Expert Rev Anti Infect Ther. 2023;21(2):149\u201366. Epub 2023 Jan 31.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"9","key":"9899_CR38","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/j.jiph.2023.06.009","volume":"16","author":"F Cal\u00f2","year":"2023","unstructured":"Cal\u00f2 F, Onorato L, De Luca I, et al. Outcome of patients with carbapenem-resistant Acinetobacter baumannii infections treated with cefiderocol: a multicenter observational study. J Infect Public Health. 2023;16(9):1485\u201391. Epub 2023 Jun 14.","journal-title":"J Infect Public Health"},{"issue":"7","key":"9899_CR39","doi-asserted-by":"publisher","first-page":"ofad329","DOI":"10.1093\/ofid\/ofad329","volume":"10","author":"M Giannella","year":"2023","unstructured":"Giannella M, Verardi S, Karas A, et al. ARES Study Group. Carbapenem-Resistant Acinetobacter spp infection in critically ill patients with Limited Treatment options: a descriptive study of Cefiderocol Therapy during the COVID-19 pandemic. Open Forum Infect Dis. 2023;10(7):ofad329. https:\/\/doi.org\/10.1093\/ofid\/ofad329.","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"9899_CR40","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1473-3099(21)00194-8","volume":"21","author":"JE Choby","year":"2021","unstructured":"Choby JE, Ozturk T, Satola SW, et al. Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens. Lancet Infect Dis. 2021;21(5):597\u20138. https:\/\/doi.org\/10.1016\/S1473-3099(21)00194-8.","journal-title":"Lancet Infect Dis"},{"key":"9899_CR41","doi-asserted-by":"publisher","unstructured":"Pintado V, Ruiz-Garbajosa P, Aguilera-Alonso D et al. Executive summary of the consensus document of the Spanish Society of Infectious diseases and Clinical Microbiology (SEIMC) on the diagnosis and antimicrobial treatment of infections due to carbapenem-resistant Gram-negative bacteria. Enferm Infecc Microbiol Clin (Engl Ed). 2023 Jun-Jul;41(6):360\u201370. https:\/\/doi.org\/10.1016\/j.eimce.2022.06.014. Epub 2022 Dec 13.","DOI":"10.1016\/j.eimce.2022.06.014"}],"updated-by":[{"DOI":"10.1186\/s12879-024-09979-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000}}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09899-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-09899-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09899-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T08:01:45Z","timestamp":1727769705000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-09899-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,13]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["9899"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-09899-5","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12879-024-09979-6","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,13]]},"assertion":[{"value":"9 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12879-024-09979-6","URL":"https:\/\/doi.org\/10.1186\/s12879-024-09979-6","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"967"}}